Indoco Remedies · NSE: INDOCO · BSE: 532612
Q3 FY25 results · Oct–Dec 2024
Indoco Remedies reported revenue from operations of ₹410.55 crore (down 10.6% from Q3 FY24) and net loss of ₹28.40 crore for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 410.55 | 459.42 | −10.6% | 432.66 | −5.1% |
| Other income | 0.85 | 2.35 | −63.8% | 1.56 | −45.5% |
| Total income | 411.40 | 461.77 | −10.9% | 434.22 | −5.3% |
| Profit before tax | (30.96) | 22.63 | Turned loss | (4.84) | Loss widened |
| Net profit for the period | (28.40) | 15.56 | Turned loss | (10.01) | Loss widened |
| Attributable to shareholders of the company | (26.39) | 16.30 | Turned loss | (9.57) | Loss widened |
| EPS, basic (₹) | (3.08) | 1.69 | Turned loss | (1.09) | Loss widened |
| Net margin (%) | -6.9 | 3.4 | -2.3 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 372.98 | 449.05 | −16.9% | 396.53 | −5.9% |
| Other income | 4.26 | 2.93 | +45.4% | 4.20 | +1.4% |
| Total income | 377.24 | 451.98 | −16.5% | 400.73 | −5.9% |
| Profit before tax | (13.36) | 27.02 | Turned loss | 17.38 | Turned loss |
| Net profit for the period | (10.23) | 20.01 | Turned loss | 12.79 | Turned loss |
| EPS, basic (₹) | (1.11) | 2.17 | Turned loss | 1.39 | Turned loss |
| Net margin (%) | -2.7 | 4.5 | 3.2 |
Consolidated
- Filed with BSE
- 21 Jan 2025, 16:25 IST
- Board meeting
- 21 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 21 Jan 2025, 16:25 IST
- Board meeting
- 21 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE